In short
Currently, there is 1 ongoing clinical trial investigating treatments for tumour thrombosis, specifically in patients with advanced pancreatic cancer. This trial is examining whether preventing blood clots can improve outcomes for cancer patients receiving chemotherapy.
Clinical trial locations
- Greece
Study on the Effect of Tinzaparin Sodium on Survival in Patients with Advanced Pancreatic Cancer
This clinical trial is investigating whether tinzaparin sodium, a medication used to prevent blood clots, can improve outcomes for patients with advanced pancreatic cancer. The study focuses on understanding if preventing blood clots during chemotherapy can help patients live longer without their cancer progressing.
Who can participate:
- Adults aged 18 years or older with locally advanced or metastatic pancreatic cancer confirmed by appropriate tests
- Patients planning to start first-line chemotherapy with NabG (Nab-Paclitaxel)
- Patients with an ECOG performance score of 0-2, meaning they can perform daily activities with varying levels of independence
- Life expectancy of more than 6 months
- Ability to provide written informed consent
Who cannot participate:
- Patients not receiving treatment for advanced pancreatic cancer
- Patients not undergoing chemotherapy with NabG
- Patients who are not eligible for venous thromboembolism prevention
- Patients unable to receive tinzaparin medication
- Patients outside the specified age range
- Members of vulnerable populations requiring special protection
What the trial involves:
The main goal of this study is to evaluate whether preventing blood clots with tinzaparin sodium can improve progression-free survival in patients with advanced pancreatic cancer. Progression-free survival refers to the length of time during and after treatment that a patient lives without their cancer getting worse.
Participants will receive tinzaparin sodium through subcutaneous injections, meaning the medication is injected just under the skin. The medication comes in pre-filled syringes with different dosage strengths depending on individual treatment needs. Patients will receive this medication alongside their standard chemotherapy regimen.
Throughout the study, researchers will monitor participants for any blood clot events, such as deep vein thrombosis or pulmonary embolism. They will also assess bleeding events, overall response to treatment, quality of life changes, and overall survival rates. Regular check-ups will be conducted to track the health and progress of participants.
Investigational drugs being tested:
Tinzaparin sodium is a low molecular weight heparin that works by inhibiting specific factors in the blood clotting process. In this study, it is being used to prevent venous thromboembolism, a condition where blood clots form in the veins, which is a common complication in cancer patients. The study aims to determine if using tinzaparin can reduce this risk and improve how long patients live without cancer progression.
Nab-Paclitaxel (NabG) is a chemotherapy drug used as first-line treatment for advanced pancreatic cancer. It works by stopping cancer cells from growing and dividing. The trial is evaluating how effective this chemotherapy is when combined with tinzaparin in preventing cancer progression.
The study is being conducted in Greece and is expected to conclude by August 2025.
Summary
This ongoing clinical trial represents an important investigation into whether preventing blood clots can improve outcomes for patients with advanced pancreatic cancer. The single trial currently available is taking place in Greece and focuses specifically on patients starting first-line chemotherapy with Nab-Paclitaxel.
The study highlights the connection between cancer treatment and blood clot prevention, recognizing that patients with advanced cancer are at increased risk of developing dangerous blood clots. By testing tinzaparin sodium alongside standard chemotherapy, researchers hope to determine whether this preventive approach can help patients live longer without their cancer progressing.
Patients interested in participating should discuss this trial with their healthcare provider to determine if they meet the eligibility criteria and whether this treatment approach might be appropriate for their individual situation.
